In prostate cancer, METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis, and inhibition of METTL1 activity leads to favorable changes within the tumor, such as an increase in anti-tumor cytokines and infiltration of cytotoxic immune cells, including M1 macrophages and CD8+ T cells (8). This evidence concerns the gene METTL1 and neoplasm.